Mead Johnson Nutrition Co. (NYSE:MJN) has been assigned a consensus rating of “Hold” from the thirteen research firms that are covering the stock. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $94.45.

MJN has been the topic of a number of research analyst reports. Susquehanna reaffirmed a “hold” rating and set a $95.00 target price on shares of Mead Johnson Nutrition in a report on Monday, August 29th. Credit Suisse Group AG set a $100.00 price target on Mead Johnson Nutrition and gave the stock a “buy” rating in a report on Monday, September 12th. Goldman Sachs Group Inc. cut their price target on Mead Johnson Nutrition from $96.00 to $85.00 and set a “neutral” rating on the stock in a report on Tuesday, September 27th. Citigroup Inc. cut their price target on Mead Johnson Nutrition from $106.00 to $103.00 and set a “buy” rating on the stock in a report on Thursday, September 8th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $97.00 price target on shares of Mead Johnson Nutrition in a report on Friday, September 23rd.

In related news, SVP Graciela Monteagudo sold 45,873 shares of the firm’s stock in a transaction that occurred on Friday, August 5th. The stock was sold at an average price of $87.64, for a total value of $4,020,309.72. Following the sale, the senior vice president now directly owns 13,800 shares in the company, valued at approximately $1,209,432. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Kimberly A. Casiano sold 710 shares of the firm’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $89.75, for a total value of $63,722.50. Following the completion of the sale, the director now owns 7,110 shares in the company, valued at $638,122.50. The disclosure for this sale can be found here. 0.50% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of MJN. Searle & CO. purchased a new position in shares of Mead Johnson Nutrition during the third quarter valued at about $307,000. BNP Paribas Arbitrage SA boosted its position in shares of Mead Johnson Nutrition by 61.4% in the third quarter. BNP Paribas Arbitrage SA now owns 15,887 shares of the company’s stock valued at $1,255,000 after buying an additional 6,046 shares during the period. Eqis Capital Management Inc. boosted its position in shares of Mead Johnson Nutrition by 47.8% in the third quarter. Eqis Capital Management Inc. now owns 3,855 shares of the company’s stock valued at $305,000 after buying an additional 1,247 shares during the period. Washington Trust Bank boosted its position in shares of Mead Johnson Nutrition by 2.2% in the third quarter. Washington Trust Bank now owns 37,240 shares of the company’s stock valued at $2,942,000 after buying an additional 799 shares during the period. Finally, Williams Jones & Associates LLC purchased a new position in shares of Mead Johnson Nutrition during the second quarter valued at about $984,000. Hedge funds and other institutional investors own 96.93% of the company’s stock.

Shares of Mead Johnson Nutrition (NYSE:MJN) opened at 80.19 on Monday. The firm’s 50-day moving average price is $79.94 and its 200-day moving average price is $84.66. Mead Johnson Nutrition has a 52-week low of $65.53 and a 52-week high of $94.40. The stock has a market capitalization of $14.81 billion, a P/E ratio of 30.17 and a beta of 1.26.

Mead Johnson Nutrition (NYSE:MJN) last released its earnings results on Thursday, July 28th. The company reported $0.88 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.10. Mead Johnson Nutrition had a negative return on equity of 194.30% and a net margin of 13.28%. The company had revenue of $941.50 million for the quarter, compared to the consensus estimate of $967.25 million. During the same quarter last year, the business posted $0.76 EPS. Mead Johnson Nutrition’s quarterly revenue was down 8.8% compared to the same quarter last year. Equities analysts forecast that Mead Johnson Nutrition will post $3.48 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Monday, October 3rd. Investors of record on Monday, September 19th were given a $0.4125 dividend. This represents a $1.65 annualized dividend and a yield of 2.06%. The ex-dividend date of this dividend was Thursday, September 15th. Mead Johnson Nutrition’s dividend payout ratio is currently 62.03%.

Mead Johnson Nutrition Company Profile

Mead Johnson Nutrition Company (Mead Johnson) is a pediatric nutrition company. The Company manufactures, distributes and sells infant formulas, children’s nutrition and other nutritional products. The Company operates through three segments: Asia, North America/Europe and Latin America. Its product portfolio includes routine and specialty infant formulas, children’s milks and milk modifiers, dietary supplements for pregnant and breastfeeding mothers, pediatric vitamins, and products for pediatric metabolic disorders.

5 Day Chart for NYSE:MJN

Receive News & Stock Ratings for Mead Johnson Nutrition Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mead Johnson Nutrition Co. and related stocks with our FREE daily email newsletter.